quinazolines has been researched along with sildenafil citrate in 11 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 7 (63.64) | 29.6817 |
2010's | 2 (18.18) | 24.3611 |
2020's | 2 (18.18) | 2.80 |
Authors | Studies |
---|---|
Krupinski, J; Macor, JE; Normandin, D; Pongrac, R; Rotella, DP; Seliger, L; Sun, Z; Zhu, Y | 1 |
Andersson, K; Fujiwara, M; Persson, K | 1 |
Hirose, R; Ichimura, M; Irie, J; Nomoto, Y; Ohno, T; Okumura, H; Onoda, Y; Takai, H; Yoshimatsu, A | 1 |
Barras, M; Palea, S | 1 |
Gonzalez, RR; Kaplan, SA; Te, AE | 1 |
Sciarra, A | 1 |
Hauzeur, C; Roumeguère, T; Schulman, C; Vanhaeverbeek, M; Wespes, E; Zouaoui Boudjeltia, K | 1 |
Akyüz, M; Güneş, M; Kalkan, S; Karaman, MI; Koca, O; Öztürk, Mİ | 1 |
Ashby, CR; Chen, ZS; Kathawala, RJ; Wang, YJ | 1 |
Ayad, MM; Hosny, MM; Metias, YM | 1 |
Chatturong, U; Chootip, K; Demougeot, C; Gleeson, MP; Ingkaninan, K; Konsue, A; Martin, H; Sermsenaphorn, S; Somarin, T; Temkitthawon, P; Totoson, P | 1 |
2 review(s) available for quinazolines and sildenafil citrate
Article | Year |
---|---|
Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
Topics: Aged; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Prostatism; Purines; Quality of Life; Quinazolines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2009 |
Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs.
Topics: Antineoplastic Agents; Benzamides; Benzylisoquinolines; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Imidazoles; Lapatinib; Multidrug Resistance-Associated Proteins; Piperazines; Purines; Pyrimidines; Quinazolines; Sildenafil Citrate; Sulfonamides; Sulfones; Taxoids; Triazines; Vardenafil Dihydrochloride | 2014 |
2 trial(s) available for quinazolines and sildenafil citrate
Article | Year |
---|---|
Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Pilot Projects; Piperazines; Prostatic Hyperplasia; Purines; Quinazolines; Sildenafil Citrate; Sulfones; Treatment Outcome; Urination Disorders | 2007 |
Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Drug Therapy, Combination; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Purines; Quinazolines; Sildenafil Citrate; Sulfones; Urination Disorders | 2012 |
7 other study(ies) available for quinazolines and sildenafil citrate
Article | Year |
---|---|
N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Imidazoles; In Vitro Techniques; Male; Penis; Phosphodiesterase Inhibitors; Piperazines; Purines; Purinones; Quinazolines; Rabbits; Sildenafil Citrate; Structure-Activity Relationship; Sulfones | 2000 |
Nitric oxide-induced cGMP accumulation in the mouse bladder is not related to smooth muscle relaxation.
Topics: Animals; Arginine; Carbachol; Cyclic AMP; Cyclic GMP; Dose-Response Relationship, Drug; Electric Stimulation; Enzyme Inhibitors; Female; In Vitro Techniques; Mice; Mice, Inbred BALB C; Molsidomine; Muscle Relaxation; Muscle, Smooth; Nitric Oxide Donors; Nitric Oxide Synthase; Nitroarginine; Nitroprusside; Phosphodiesterase Inhibitors; Piperazines; Piperidines; Purines; Quinazolines; Sildenafil Citrate; Sulfones; Urethra; Urinary Bladder | 2000 |
KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Blood Platelets; Cyclic AMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Dogs; Dose-Response Relationship, Drug; Imidazoles; Isoenzymes; Kinetics; Molecular Structure; Nitroglycerin; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Platelet Aggregation Inhibitors; Purines; Quinazolines; Rabbits; Sildenafil Citrate; Sulfones | 2001 |
Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum.
Topics: Adrenergic alpha-Antagonists; Animals; Erectile Dysfunction; Male; Muscle Relaxation; Penile Erection; Phentolamine; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Purines; Quinazolines; Rabbits; Sildenafil Citrate; Sulfones | 2003 |
Lower urinary tract symptoms (LUTS) and sexual dysfunction (SD): new targets for new combination therapies?
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Drug Therapy, Combination; Enzyme Inhibitors; Erectile Dysfunction; Humans; Male; Middle Aged; Piperazines; Prevalence; Prostatic Hyperplasia; Purines; Quality of Life; Quinazolines; Risk Factors; Sildenafil Citrate; Sulfones; Urination Disorders | 2007 |
Green micellar liquid chromatographic analysis of alfuzosin hydrochloride and sildenafil citrate in a binary mixture compared to classical RPLC with stability indicating studies.
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Micelles; Quinazolines; Sildenafil Citrate | 2022 |
Quinazoline-based human phosphodiesterase 5 inhibitors exhibited a selective vasorelaxant effect on rat isolated pulmonary arteries involving NO-sGC-cGMP pathway and calcium inhibitory effects.
Topics: Animals; Calcium; Cyclic GMP; Humans; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Quinazolines; Rats; Sildenafil Citrate; Vasodilation; Vasodilator Agents | 2022 |